Cytokinetics, Incorporated Contracts & Agreements

Fifth Amendment to Lease, dated November 27, 2023, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 28, 2024)

Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description (Filed With SEC on October 3, 2023)

Description of Director Compensation (Filed With SEC on November 4, 2022)

Indenture, dated as of July 6, 2022, between Cytokinetics, Incorporated and U.S. Bank Trust Company, National Association, as trustee (Filed With SEC on July 6, 2022)

Third Amendment to Lease, dated January 26, 2021, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 25, 2022)

License and Collaboration Agreement, dated December 20, 2021, by and between the Company and Ji Xing Pharmaceuticals Limited (Filed With SEC on February 25, 2022)

Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Master Fund, Ltd (Filed With SEC on February 25, 2022)

Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Innovation Master Fund, Ltd (Filed With SEC on February 25, 2022)

Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Venture Fund Limited (Filed With SEC on February 25, 2022)

Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company (Filed With SEC on February 25, 2022)

Amendment No. 1 to Royalty Purchase Agreement, dated January 7, 2022, by and between the Company and RPI Finance Trust (Filed With SEC on February 25, 2022)

Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between the Company and Royalty Pharma Investments 2019 ICAV (Filed With SEC on February 25, 2022)

Fourth Amendment to Loan and Security Agreement, dated June 30, 2021, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 5, 2021)

Amended and Restated 2004 Equity Incentive Plan (Filed With SEC on November 5, 2021)

Eighth Amendment to Lease, dated May 18, 2021, by and between the Company and Britannia Pointe Grand Limited Partnership (Filed With SEC on August 6, 2021)

Underwriting Agreement, dated as of July 20, 2021, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC (Filed With SEC on July 21, 2021)

First Amendment to Lease, dated May 12, 2020, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 26, 2021)

Second Amendment to Lease, dated January 26, 2021, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 26, 2021)

Letter Agreement, dated December 23, 2020, by and between Company and Astellas amending the License and Collaboration Agreement for Other Skeletal Sarcomere Activators, dated... (Filed With SEC on February 26, 2021)

License and Collaboration Agreement, dated July 14, 2020, by and between the Company and Ji Xing Pharmaceuticals Limited (Filed With SEC on November 6, 2020)

Funding Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Filed With SEC on November 6, 2020)

Royalty Purchase Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Filed With SEC on November 6, 2020)

Form of Common Stock Purchase Agreement, dated July 14, 2020 (Filed With SEC on November 6, 2020)

Third Amendment to Loan and Security Agreement, dated July 16, 2020, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 6, 2020)

Fast Skeletal Regulatory Activator Agreement, dated April 23, 2020, by and between the Company and Astellas Pharma Inc (Filed With SEC on August 10, 2020)

Underwriting Agreement, dated as of July 16, 2020, by and among Cytokinetics, Incorporated, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co (Filed With SEC on July 17, 2020)

Description of Securities (Filed With SEC on March 4, 2020)

Compensation Information for the Companys Named Executive Officers (Filed With SEC on February 28, 2020)

Underwriting Agreement, dated November 7, 2019, by and between the Company and Morgan Stanley & Co. LLC as representative of the several underwriters named therein (Filed With SEC on November 13, 2019)

Base Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on November 13, 2019)

First Supplemental Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (including the form of 4.00% Convertible Senior Note due... (Filed With SEC on November 13, 2019)

First Amendment to Loan and Security Agreement, dated as of November 6, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 13, 2019)

Second Amendment to Loan and Security Agreement, dated as of November 7, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 13, 2019)

Seventh Amendment to Lease, dated July 11, 2019, by and between the Company and Britannia Pointe Grand Limited Partnership (Filed With SEC on November 1, 2019)

Form of Warrant Issuable to Oxford Finance LLC (Filed With SEC on August 9, 2019)

Form of Warrant Issuable to Silicon Valley Bank (Filed With SEC on August 9, 2019)

Loan and Security Agreement, dated as of May 17, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on August 9, 2019)

Controlled Equity Offering Sales Agreement, dated as of March 6, 2019, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on March 7, 2019)

Amendment No. 8, dated November 30, 2016, to the Collaboration and Option Agreement by and between the Company and Amgen Inc (Filed With SEC on March 7, 2019)

Amendment No. 9, dated February 6, 2019, to the Collaboration and Option Agreement by and between the Company and Amgen Inc (Filed With SEC on March 7, 2019)

Amendment to Collaboration Agreement; Joint Development Committee Membership (Filed With SEC on August 7, 2018)

Second Amendment to Loan and Security Agreement by and among the Company, Oxford Finance LLC and Silicon Valley Bank, dated as of October 27, 2017 (Filed With SEC on March 5, 2018)

Fifth Amendment to Lease, dated December 18, 2017, by and between the Company and Britannia Pointe Grand Limited Partnership (Filed With SEC on March 5, 2018)

Amendment to Collaboration Agreement between the Company and Astellas Pharma Inc., dated December 21, 2017 (Filed With SEC on March 5, 2018)

Compensation Information for the Companys Named Executive Officers (Filed With SEC on March 2, 2018)

Controlled Equity OfferingSM Sales Agreement, dated November 3, 2017, by and between Cytokinetics, Incorporated and Cantor Fitzgerald & Co (Filed With SEC on November 6, 2017)

Amended and Restated 2004 Equity Incentive Plan (Filed With SEC on November 3, 2017)

Exhibit (Filed With SEC on August 4, 2017)

5,260,000Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT (Filed With SEC on May 9, 2017)

ROYALTYPURCHASE AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND RPIFINANCE TRUST DATED AS OF FEBRUARY 1, 2017 TABLE OF CONTENTS (Filed With SEC on March 6, 2017)

CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 6, 2017)

Compensation Information for Named Executive Officers (Filed With SEC on March 2, 2017)

AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 3, 2016)

LETTEROF AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND AMGEN INC. AND LES LABORATOIRES SERVIER AND INSTITUT DERECHERCHES INTERNATIONALES SERVIER DATED AUGUST 29, 2016 (Filed With SEC on November 3, 2016)

FOURTH AMENDMENT TO BUILD TO SUIT LEASE (Filed With SEC on May 5, 2016)

WARRANT TO PURCHASESTOCK (Filed With SEC on March 3, 2016)

LOAN ANDSECURITY AGREEMENT (Filed With SEC on March 3, 2016)

Compensation Information for Named Executive Officers (Filed With SEC on February 25, 2016)

CYTOKINETICS, INCORPORATED Shares of Common Stock (par value$0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on September 4, 2015)

CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS:FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS:MAY 22, 2013 AMENDED TO... (Filed With SEC on August 5, 2015)

CYTOKINETICS, INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:FEBRUARY 3, 2015 APPROVED BY THE STOCKHOLDERS:MAY 20, 2015 EFFECTIVE DATE: NOVEMBER... (Filed With SEC on August 5, 2015)

AMENDMENT NO. 7 TO COLLABORATION AND OPTION AGREEMENT (Filed With SEC on May 4, 2015)

Amended andRestated License and Collaboration Agreement by and between Cytokinetics, Inc. and Astellas Pharma Inc. (Filed With SEC on March 6, 2015)

Compensation Information for Named Executive Officers (Filed With SEC on March 2, 2015)

CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on December 23, 2014)

CYTOKINETICS, INCORPORATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 7, 2014)

2013 Bonus and 2014 Compensation Information for Named Executive Officers (Filed With SEC on February 27, 2014)

4,375,000 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT (Filed With SEC on February 20, 2014)

CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED (As amended by the Board of Directors on February 6, 2013; Stockholder approval May 22, 2013; updated following... (Filed With SEC on August 7, 2013)

CYTOKINETICS, INCORPORATED 2004 EMPLOYEE STOCK PURCHASE PLAN (As amended by the Board of Directors on February 6, 2013; stockholder approval May 22, 2013; updated following... (Filed With SEC on August 7, 2013)

AMENDMENT NO. 6 TO COLLABORATION AND OPTION AGREEMENT (Filed With SEC on August 7, 2013)

License andCollaboration Agreement by and between Cytokinetics, Inc. and Astellas Pharma Inc. (Filed With SEC on August 7, 2013)

CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on June 12, 2013)

CYTOKINETICS, INCORPORATED 2004 EMPLOYEE STOCK PURCHASE PLAN (As amended by the Board of Directors on March 15, 2006 and approved by the Stockholders May 25, 2006, asamended by... (Filed With SEC on March 15, 2013)

AMENDMENT NO. 2 TO CONSULTING AGREEMENT (Filed With SEC on March 15, 2013)

CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED FORM OF OPTION AGREEMENT (Filed With SEC on March 15, 2013)

CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on March 15, 2013)

2012 Bonus and 2013 Compensation Information for Named Executive Officers (Filed With SEC on March 11, 2013)

Warrant to Purchase Common Stock of Cytokinetics, Incorporated (Filed With SEC on August 6, 2012)

CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED (Filed With SEC on August 6, 2012)

55,921,055 Shares of Common Stock Warrants to Purchase 33,552,633 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT (Filed With SEC on June 20, 2012)

23,026 Shares of Series B Convertible PreferredStock Warrants to Purchase 13,815,600 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT (Filed With SEC on June 20, 2012)

CYTOKINETICS, INCORPORATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE... (Filed With SEC on June 20, 2012)

Warrant to Purchase Common Stock of Cytokinetics, Incorporated (Filed With SEC on June 20, 2012)

AMENDMENT NO. 1 TO CONSULTING AGREEMENT (Filed With SEC on May 4, 2012)

CYTOKINETICS, INC. CONSULTING AGREEMENT (Filed With SEC on March 13, 2012)

CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on December 2, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on August 4, 2011)

CYTOKINETICS, INCORPORATED (Filed With SEC on June 13, 2011)

CYTOKINETICS, INCORPORATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE... (Filed With SEC on April 18, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 18, 2011)

Warrant to Purchase Common Stock of Cytokinetics, Incorporated (Filed With SEC on April 18, 2011)

guidance concerning revenues, research and development expenses and general and administrative expenses for 2011 (Filed With SEC on March 11, 2011)

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on October 26, 2010)

Current assets (Filed With SEC on August 4, 2010)

guidance concerning revenues, research and development expenses and general and administrative expenses for 2010 (Filed With SEC on March 11, 2010)

Current assets (Filed With SEC on August 6, 2009)

7,106,600 Shares of Common Stock and Warrants to Purchase up to 3,553,300 Shares of Common Stock CYTOKINETICS, INCORPORATED PLACEMENT AGENT AGREEMENT (Filed With SEC on May 19, 2009)

SUBSCRIPTION AGREEMENT (Filed With SEC on May 19, 2009)

CYTOKINETICS, INCORPORATED WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on May 19, 2009)

guidance concerning revenues, research and development expenses and general and administrative expenses for 2009 (Filed With SEC on March 12, 2009)

Current assets (Filed With SEC on August 5, 2008)

GlaxoSmithKline 2301 Renaissance Boulevard Building #510RN0420 King of Prussia, Pennsylvania 19406 Attn: Vinod Ramachandran, Ph.D. (Filed With SEC on June 20, 2008)

CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN (as amended and restated as of May 22,2008) (Filed With SEC on May 29, 2008)

CYTOKINETICS, INC. SCIENTIFIC ADVISORY BOARD CONSULTING AGREEMENT (Filed With SEC on April 2, 2008)

CYTOKINETICS, INCORPORATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on April 2, 2008)

WARRANT (Filed With SEC on October 15, 2007)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 15, 2007)

GlaxoSmithKline2301 Renaissance BoulevardBuilding #510RN0420King of Prussia, Pennsylvania 19406 Attn: Scott Klesmer (Filed With SEC on June 19, 2007)

CYTOKINETICS, INCORPORATED AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 21, 2007)

Current assets (Filed With SEC on May 9, 2007)

the initiation, progress, timing, scope and anticipated date of completion of clinical trials and development for our drug candidates and potential drug candidates by ourselves,... (Filed With SEC on March 12, 2007)

CYTOKINETICS, INCORPORATED (Filed With SEC on January 3, 2007)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 3, 2007)

Exhibit No (Filed With SEC on December 7, 2006)

Exhibit No (Filed With SEC on November 27, 2006)

Current assets (Filed With SEC on August 8, 2006)

Exhibit No (Filed With SEC on June 19, 2006)

Exhibit No (Filed With SEC on March 22, 2006)

the initiation, progress, timing, scope and anticipated date of completion of preclinical research, clinical trials and development for our drug candidates and potential drug... (Filed With SEC on March 10, 2006)

Name and Title (Filed With SEC on March 7, 2006)

Exhibit No (Filed With SEC on January 20, 2006)

Exhibit No (Filed With SEC on January 18, 2006)

Sublease, dated as of November 29, 2005, by and among the Company and the parties named therein (Filed With SEC on December 13, 2005)

CYTOKINETICS,INCORPORATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on December 12, 2005)

Current assets (Filed With SEC on November 10, 2005)

Current assets (Filed With SEC on August 12, 2005)

Current Assets (Filed With SEC on May 12, 2005)

Amendment No. 2 To Collaboration Agreement (Filed With SEC on March 14, 2005)

Current Assets (Filed With SEC on November 12, 2004)

Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid... (Filed With SEC on April 27, 2004)

Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid (Filed With SEC on March 11, 2004)

Category

Industry

Companies

Contracts

Cytokinetics, Incorporated Contracts & Agreements